Health Canada has suspended sales of Allergan’s Biocell breast implants due to a higher incidence of a rare breast cancer in patients with macro-textured breast implants than other implants.
The Allergan (NYSE: AGN) Biocell breast implants are the only macro-textured implants available in Canada. The regulatory agency instituted the ban based on the results of a 2017 safety review on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Allergan has agreed to voluntarily recall unused Biocell devices from the Canadian market, according to Health Canada. Allergan’s other breast implant products are not affected by this decision.
Get the full story on our sister site, Medical Design & Outsourcing.